Incidence, Treatment Intensity, and Incremental Annual Expenditures for Patients Experiencing a Cardiac Implantable Electronic Device Infection: Evidence from a Large US Payer Database 1-Year Post Implantation

Circulation: Arrhythmia and Electrophysiology

Volumn 9, Issue 8, 2016, Pages

  Sohail, M Rizwan ^a   Eby, Elizabeth L ^b   Ryan, Michael P ^c   Gunnarsson, Candace ^c   Wright, Laura A ^d   Greenspon, Arnold J ^e  

^a Mayo Clinic   (United States)

^b Medtronic plc   (United States)

^c Health Economics and Outcomes Research   (United States)

^d CTI Clinical Trial and Consulting Services Inc   (United States)

^e THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

device removal; healthcare costs; incidence; infection; outpatients

Indexed keywords

AGED; ARTICLE; CARDIAC IMPLANT; DEVICE INFECTION; DEVICE REMOVAL; FEMALE; GENERATOR; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; IMPLANTATION; INCIDENCE; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; SEPSIS; ADVERSE DEVICE EFFECT; ARTIFICIAL HEART PACEMAKER; COMORBIDITY; ECONOMICS; HEALTH SURVEY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFECTION; RISK FACTOR; UNITED STATES;

AGED; COMORBIDITY; DEFIBRILLATORS, IMPLANTABLE; DEVICE REMOVAL; FEMALE; HEALTH EXPENDITURES; HUMANS; INCIDENCE; MALE; PACEMAKER, ARTIFICIAL; POPULATION SURVEILLANCE; PROSTHESIS-RELATED INFECTIONS; RISK FACTORS; UNITED STATES;

EID: 84983238358     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.116.003929     Document Type: Article

References (30)

1. th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009-a World Society of Arrhythmia's project. Pacing Clin Electrophysiol 2011 34 1013 1027. doi: 10.1111/j.1540-8159.2011.03150.x
2. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT, Pavri BB, Kurtz SM, Trends in permanent pacemaker implantation in the United States from 1993 to 2009: increasing complexity of patients and procedures. J Am Coll Cardiol 2012 60 1540 1545. doi: 10.1016/j.jacc.2012.07.017
3. Uslan DZ, Tleyjeh IM, Baddour LM, Friedman PA, Jenkins SM, St Sauver JL, Hayes DL, Temporal trends in permanent pacemaker implantation: a population-based study. Am Heart J 2008 155 896 903. doi: 10.1016/j.ahj.2007.12.022
4. Zhan C, Baine WB, Sedrakyan A, Steiner C, Cardiac device implantation in the United States from 1997 through 2004: a population-based analysis. J Gen Intern Med 2008 23 suppl 1 13 19
5. Bradshaw PJ, Stobie P, Knuiman MW, Briffa TG, Hobbs MS, Trends in the incidence and prevalence of cardiac pacemaker insertions in an ageing population. Open Heart 2014 1 e000177. doi: 10.1136/openhrt-2014-000177
6. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT, Pavri BB, Kurtz SM, 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol 2011 58 1001 1006. doi: 10.1016/j.jacc.2011.04.033
7. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML, Multicenter Automatic Defibrillator Implantation Trial II Investigators Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 346 877 883. doi: 10.1056/NEJMoa013474
8. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 352 225 237. doi: 10.1056/NEJMoa043399
9. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M, Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996 335 1933 1940. doi: 10.1056/NEJM199612263352601
10. Voigt A, Shalaby A, Saba S, Continued rise in rates of cardiovascular implantable electronic device infections in the United States: temporal trends and causative insights. Pacing Clin Electrophysiol 2010 33 414 419. doi: 10.1111/j.1540-8159.2009.02569.x
11. Sohail MR, Henrikson CA, Braid-Forbes MJ, Forbes KF, Lerner DJ, Mortality and cost associated with cardiovascular implantable electronic device infections. Arch Intern Med 2011 171 1821 1828. doi: 10.1001/archinternmed.2011.441
12. Hansen LG, Chang S, White Paper. Health research data for the real world: The MarketScan databases. Truven Health Analytics 2012. http://truvenhealth.com/portals/0/assets/PH-11238-0612-TEMP-MarketScan-WP-FINAL.pdf. Accessed January 14, 2016
13. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA, Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005 43 1130 1139
14. Elixhauser A, Steiner C, Harris DR, Coffey RM, Comorbidity measures for use with administrative data. Med Care 1998 36 8 27
15. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB, Masoudi FA, Okum EJ, Wilson WR, Beerman LB, Bolger AF, Estes NA III, Gewitz M, Newburger JW, Schron EB, Taubert KA, American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; Council on Cardiovascular Disease in Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Interdisciplinary Council on Quality of Care; American Heart Association Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010 121 458 477. doi: 10.1161/CIRCULATIONAHA.109.192665
16. LE KY, Sohail MR, Friedman PA, Uslan DZ, Cha SS, Hayes DL, Wilson WR, Steckelberg JM, Baddour LM, Mayo Cardiovascular Infections Study Group Clinical predictors of cardiovascular implantable electronic device-related infective endocarditis. Pacing Clin Electrophysiol 2011 34 450 459. doi: 10.1111/j.1540-8159.2010.02991.x
17. Prutkin JM, Reynolds MR, Bao H, Curtis JP, Al-Khatib SM, Aggarwal S, Uslan DZ, Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry. Circulation 2014 130 1037 1043. doi: 10.1161/CIRCULATIONAHA.114.009081
18. Yang DD, Jarrod E, A unified approach to measuring the effect size between two groups using SAS®. Proceedings of the SAS® Global Forum 2012 Conference 2012
19. Polyzos KA, Konstantelias AA, Falagas ME, Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace 2015 17 767 777. doi: 10.1093/europace/euv053
20. Kusumoto FM, Calkins H, Boehmer J, Buxton AE, Chung MK, Gold MR, Hohnloser SH, Indik J, Lee R, Mehra MR, Menon V, Page RL, Shen WK, Slotwiner DJ, Stevenson LW, Varosy PD, Welikovitch L, HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation 2014 130 94 125. doi: 10.1161/CIR.0000000000000056
21. Sandoe JA, Barlow G, Chambers JB, Gammage M, Guleri A, Howard P, Olson E, Perry JD, Prendergast BD, Spry MJ, Steeds RP, Tayebjee MH, Watkin R, British Society for Antimicrobial Chemotherapy; British Heart Rhythm Society; British Cardiovascular Society; British Heart Valve Society; British Society for Echocardiography Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). J Antimicrob Chemother 2015 70 325 359. doi: 10.1093/jac/dku383
22. Ahmed FZ, James J, Cunnington C, Motwani M, Fullwood C, Hooper J, Burns P, Qamruddin A, Al-Bahrani G, Armstrong I, Tout D, Clarke B, Sandoe JA, Arumugam P, Mamas MA, Zaidi AM, Early diagnosis of cardiac implantable electronic device generator pocket infection using F-FDG-PET/CT. Eur Heart J Cardiovasc Imaging 2015 16 521 530. doi: 10.1093/ehjci/jeu295
23. Welch M, Uslan DZ, Greenspon AJ, Sohail MR, Baddour LM, Blank E, Carrillo RG, Danik SB, Del Rio A, Hellinger W, Le KY, Miro JM, Naber C, Peacock JE, Vikram HR, Tseng CH, Prutkin JM, MEDIC Investigators Variability in clinical features of early versus late cardiovascular implantable electronic device pocket infections. Pacing Clin Electrophysiol 2014 37 955 962. doi: 10.1111/pace.12385
24. Bloom HL, Constantin L, Dan D, De Lurgio DB, El-Chami M, Ganz LI, Gleed KJ, Hackett FK, Kanuru NK, Lerner DJ, Rasekh A, Simons GR, Sogade FO, Sohail MR, Implantation success and infection in cardiovascular implantable electronic device procedures utilizing an antibacterial envelope. Pacing Clin Electrophysiol 2011 34 133 142
25. Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM, Miller HJ, Awad SS, Crosby CT, Mosier MC, Alsharif A, Berger DH, Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med 2010 362 18 26. doi: 10.1056/NEJMoa0810988
26. Kallen AJ, Wilson CT, Larson RJ, Perioperative intranasal mupirocin for the prevention of surgical-site infections: systematic review of the literature and meta-analysis. Infect Control Hosp Epidemiol 2005 26 916 922. doi: 10.1086/505453
27. Kolek MJ, Dresen WF, Wells QS, Ellis CR, Use of an antibacterial envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients. Pacing Clin Electrophysiol 2013 36 354 361. doi: 10.1111/pace.12063
28. Mittal S, Shaw RE, Michel K, Palekar R, Arshad A, Musat D, Preminger M, Sichrovsky T, Steinberg JS, Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AigisRx antibacterial envelope. Heart Rhythm 2014 11 595 601. doi: 10.1016/j.hrthm.2013.12.013
29. Boggan JC, Baker AW, Lewis SS, Dicks KV, Durkin MJ, Moehring RW, Chen LF, Knelson LP, Hegland DD, Anderson DJ, An automated surveillance strategy to identify infectious complications after cardiac implantable electronic device procedures. Open Forum Infect Dis 2015 2 ofv128. doi: 10.1093/ofid/ofv128
30. Greenspon AJ, Prutkin JM, Sohail MR, Vikram HR, Baddour LM, Danik SB, Peacock J, Falces C, Miro JM, Blank E, Naber C, Carrillo RG, Tseng CH, Uslan DZ, Timing of the most recent device procedure influences the clinical outcome of lead-associated endocarditis results of the MEDIC (Multicenter Electrophysiologic Device Infection Cohort). J Am Coll Cardiol 2012 59 681 687. doi: 10.1016/j.jacc.2011.11.011